Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
| 0.972 Delayed Data As of Nov 25 |  +0.072 / +8.00%Today’s Change | 0.68 Today|||52-Week Range 4.34 | -58.28% Year-to-Date |
Latest ARDS News | Press Releases
| Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates Nov 21 / Zacks.com - Paid Partner Content | Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates Nov 14 / Zacks.com - Paid Partner Content |
| Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates Nov 15 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.90 |
| Today’s open | 0.97 |
| Day’s range | 0.97 - 0.97 |
| Volume | 1 |
| Average volume (3 months) | 166,249 |
| Market cap | $20.9M |
Data as of 12:59pm ET, 11/25/2022
Growth & Valuation
| Earnings growth (last year) | -54.71% |
| Earnings growth (this year) | +79.83% |
| Earnings growth (next 5 years) | +51.90% |
| Revenue growth (last year) | +53.50% |
| P/E ratio | NM |
| Price/Sales | 18.66 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NLTXNeoleukin Therapeuti... | +0.01 | +2.27% |
| ---- | ||
| ERYPErytech Pharma SA | 0.00 | 0.00% |
| ACERAcer Therapeutics In... | +0.02 | +1.71% |
Data as of 12:59pm ET, 11/25/2022
Financials
| Next reporting date | March 30, 2023 |
| EPS forecast (this quarter) | -$0.38 |
| Annual revenue (last year) | $1.5M |
| Annual profit (last year) | -$42.2M |
| Net profit margin | -2,748.73% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Los Gatos, California |
Forecasts
